Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Khirurgiia (Mosk) ; (4): 58-63, 2021.
Artículo en Ruso | MEDLINE | ID: mdl-33759470

RESUMEN

Case report is devoted to successful pancreatectomy for cancer of terminal part of common bile duct in a patient with heterotaxy syndrome. The main difficulties during dissection of pancreaticoduodenal complex arose due to anatomical disorientation and the lack of standard topographic and anatomical landmarks. Preoperative computed tomography with assessment of visceral vessel anatomy is essential in all patients with biliopancreaticoduodenal tumors. If heterotaxy syndrome is suspected, additional examination is required to detect other potential abnormalities and prepare for unusual situation.


Asunto(s)
Neoplasias del Conducto Colédoco , Síndrome de Heterotaxia , Pancreaticoduodenectomía , Conducto Colédoco/irrigación sanguínea , Conducto Colédoco/diagnóstico por imagen , Conducto Colédoco/cirugía , Neoplasias del Conducto Colédoco/complicaciones , Neoplasias del Conducto Colédoco/diagnóstico por imagen , Neoplasias del Conducto Colédoco/cirugía , Disección , Duodeno/irrigación sanguínea , Duodeno/diagnóstico por imagen , Duodeno/cirugía , Síndrome de Heterotaxia/complicaciones , Síndrome de Heterotaxia/diagnóstico , Síndrome de Heterotaxia/diagnóstico por imagen , Humanos , Páncreas/irrigación sanguínea , Páncreas/diagnóstico por imagen , Páncreas/cirugía , Cuidados Preoperatorios , Circulación Esplácnica , Tomografía Computarizada por Rayos X
2.
Khirurgiia (Mosk) ; (9): 25-31, 2019.
Artículo en Ruso | MEDLINE | ID: mdl-31532163

RESUMEN

OBJECTIVE: To evaluate the outcomes in patients undergoing surgery for metastatic renal cell carcinoma (RCC) to the pancreas. MATERIAL AND METHODS: A retrospective analysis included 54 patients with pancreatic metastases (PM) of RCC who underwent surgical treatment at the Blokhin National Cancer Medical Research Center and Vishnevsky National Medical Research Center of Surgery in 1995-2018. PM were synchronous in 6 (11%) patients and metachronous in 48 (89%) patients. Solitary metastases were identified in 35 (65%), single metastases - in 14 (26%), multiple metastases - in 5 (9%) patients. Thirty (56%) patients had isolated PM, 24 (44%) patients - PM associated with another metastatic site. The following surgical procedures were performed: distal pancreatectomy (n=30, 55%), pancreatoduodenectomy (n=12, 21%), total pancreatectomy (n=6, 12%), pancreatic head resection (n=3, 6%), middle-preserving pancreatectomy (n=1, 2%), middle pancreatectomy (n=1, 2%), cryosurgical destruction of tumor (n=1, 2%). RESULTS: Median blood loss was 950 ml (interquartile range 400-1800 ml). Postoperative complications occurred in 52% patients. The 90-day mortality rate was 6%, overall 5-year survival 74±7%, median - 84 months. CONCLUSION: Surgery is associated with an acceptable perioperative complications and long-term survival in patients with synchronous and metachronous, solitary and multiple PM of RCC, including cases of extrapancreatic disease. This approach may be considered as a management option in these patients.


Asunto(s)
Carcinoma de Células Renales/cirugía , Neoplasias Renales/patología , Neoplasias Pancreáticas/cirugía , Carcinoma de Células Renales/secundario , Humanos , Neoplasias Primarias Múltiples/cirugía , Neoplasias Primarias Secundarias/cirugía , Páncreas/patología , Páncreas/cirugía , Pancreatectomía , Neoplasias Pancreáticas/secundario , Pancreaticoduodenectomía , Estudios Retrospectivos
3.
Medicina (B Aires) ; 57(1): 29-35, 1997.
Artículo en Español | MEDLINE | ID: mdl-9435366

RESUMEN

Several studies have shown that vitamin D (Vit. D) deficiency in elderly people enhances bone mass loss. Most of these studies have been carried out in areas of low solar irradiation. In order to establish Vit. D circulating levels in elderly people in our community (34 degrees S) and their relationship with bone metabolism, 34 men and 33 women were studied at the end of the summer. These subjects, all residents of nursing homes, had a mean age of 81.9 + 8.1 years (range 69-99). Calcemia, parathyroid hormone (PTH and 25-hydroxyvitamin D (25(HO)D) were measured in serum and bone markers in serum and urine. Bone densitometry (BMD) of cortical and trabecular bone in the forearm (distal third of the radius (R33%) and ultradistal (RUD), respectively) were performed using X-ray absorptiometry. We found: 1) Low serum 25(HO)D (14.4 + 1.7 ng/ml) at summer's end. 40.5% showed levels < 10 ng/ml. 2) Secondary hyperparathyroidism (PTH: 169.4 + 30.9 pg/ml), 3) Hypocalcemia was observed in 34.5% of elderly people, 4) increased bone turnover in the subpopulation with hypovitaminosis D. 5) The serum levels of 25(HO)D correlated with BMD R33% (r = 0.55, n = 54, P < 0.001), with BMD RUD (r = 0.50, n = 54, P < 0.001) and with PTH (r = -0.44, n = 42, P < 0.01). A deficiency of Vit.D was found in our population of elderly people, probably due to diminished epidermic production of its precursors and/or to scant exposure to sunlight in the elderly. The decrease is associated to age. The positive correlation of 25(HO)D with bone mass (cortical and trabecular bone) underscores its importance for the preservation of bone mass. Hyperparathyroidism, triggered by Vit. D deficit, enhances bone loss.


Asunto(s)
Densidad Ósea , Hidroxicolecalciferoles/sangre , Deficiencia de Vitamina D/sangre , Anciano , Anciano de 80 o más Años , Argentina , Densitometría , Femenino , Humanos , Institucionalización , Masculino , Casas de Salud , Estaciones del Año , Caracteres Sexuales
4.
Urology ; 78(3): 620-5, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21764427

RESUMEN

OBJECTIVES: To evaluate paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) in patients with poor-prognosis nonseminomatous germ cell tumor (NSGCT). Paclitaxel is an active treatment of nonseminomatous germ cell tumors. METHODS: The present study was an open-label, single-center, Phase II study. Chemotherapy-naive patients received T-BEP (paclitaxel 175 mg/m2 [day 2], cisplatin 20 mg/m2 [days 1-5], etoposide 100 mg/m2 [days 1-5], bleomycin 30 IU [days 1, 3, and 5]), and granulocyte colony-stimulating factor 300 µg (days 6-10). The number of cycles (range 4-6) was dependent on the normalization of tumor markers. Secondary resection was planned for patients with tumor marker-negative partial remission. Assessments included radiologic response, tumor markers, and safety. The primary endpoint was progression-free survival (PFS) 1 year after chemotherapy. RESULTS: Of 51 patients, 49 completed chemotherapy and were evaluable for response: 12 (25%) had a complete response, 29 (59%) were marker-negative (tumor marker normalization) and 3 (6%) were marker-positive (tumor marker decrease for ≥1 month) incomplete responders, and 5 (10%) had progressive disease. A total of 37 patients underwent secondary resection. After the treatment of 27 patients, an unplanned analysis showed inappropriate toxicity at cycle 1 (grade 3-4 infection [6 patients] resulting in 2 toxic deaths), which led to treatment modification (BEP [cycle 1], T-BEP [subsequent cycles]), with no further toxic deaths observed. Grade 3-4 adverse events included neutropenia (71%), febrile neutropenia (33%), and infection (14%). During the first year after chemotherapy, 1 patient was lost to follow-up, and 21 patients relapsed. The PFS rate at 1 year after chemotherapy was 58% (29 of 50 patients). CONCLUSIONS: T-BEP did not improve PFS in patients with poor-prognosis NSGCT. The administration of T-BEP from cycle 1 resulted in excessive toxicity but was administered safely from cycle 2.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Mediastino/tratamiento farmacológico , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Neoplasias Testiculares/tratamiento farmacológico , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bleomicina/administración & dosificación , Bleomicina/efectos adversos , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Etopósido/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de Células Germinales y Embrionarias/secundario , Pronóstico , Adulto Joven
5.
Biol Signals Recept ; 8(1-2): 126-31, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10085474

RESUMEN

In an open pilot study on the efficacy of melatonin in the treatment of sleep disorders, patients with sleep disturbances alone, patients with sleep disturbances and signs of depression and patients with sleep disorders and dementia received 3 mg melatonin p.o. for 21 days, at bed time. After 2-3 days of treatment, melatonin significantly augmented sleep quality and decreased the number of awakening episodes in patients with sleep disturbances associated or not with depression. Estimates of next-day alertness improved significantly only in patients with primary insomnia. Agitated behavior at night (sundowning) decreased significantly in dementia patients. In a second retrospective study, 14 Alzheimer's disease (AD) patients received 9 mg melatonin daily for 22-35 months. A significant improvement of sleep quality was found, while there were no significant differences between initial and final neuropsychological evaluation (Functional Assessment Tool for AD, Mini-Mental). The results indicate that melatonin can be useful to treat sleep disturbances in elderly insomniacs and AD patients.


Asunto(s)
Melatonina/uso terapéutico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/complicaciones , Demencia Vascular/complicaciones , Depresión/complicaciones , Femenino , Humanos , Masculino , Melatonina/administración & dosificación , Persona de Mediana Edad , Agitación Psicomotora/complicaciones , Agitación Psicomotora/tratamiento farmacológico , Estudios Retrospectivos , Trastornos del Inicio y del Mantenimiento del Sueño/complicaciones , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Trastornos del Sueño-Vigilia/complicaciones
6.
Rev. esp. geriatr. gerontol. (Ed. impr.) ; 39(5): 314-319, sept. 2004. tab
Artículo en Es | IBECS (España) | ID: ibc-34884

RESUMEN

Hay muy pocos trabajos publicados sobre la funcionalidad tubular en ancianos sanos y en muy ancianos. Por este motivo, decidimos explorar la función tubular renal en muy ancianos sanos (> 75 años) evaluando la excreción fraccional de sodio, urea y potasio y el gradiente transtubular de potasio mediante técnicas de restricción, sobrecarga y aclaramientos de agua y sodio. Se estudió a 44 voluntarios sanos entre ancianos (65-75 años) y muy ancianos (> 75 años), en los que se determinaron la excreción fraccional de sodio, urea y potasio y gradiente transtubular de potasio en estado basal, y a 4 personas muy ancianas se les aplicó una sobrecarga hiposalina según la técnica, habitual en nuestro laboratorio, descrita por Chaimowitz. Los datos se evaluaron mediante el test de la t de Student. Finalmente, analizamos los valores séricos de eritropoyetina (producto del intersticio peritubular proximal) en 74 voluntarios sanos (22 adultos-jóvenes, 30 ancianos y 22 muy ancianos). Para el análisis estadístico, utilizamos la los tests de la t de Student y ANOVA con ajuste de Bonferroni. De este estudio concluimos que en los muy-viejos, con respecto de los adultos-jóvenes, la función túbulo-intersticial proximal está respetada, mientras que la función del "segmento distal" de la nefrona proximal (rama gruesa ascendente del asa de Henle) está disminuida. Además, detectamos que tienen un incremento de la excreción tubular de urea, pero no de la de potasio, lo que puede explicar la merma en la capacidad de concentración-dilución urinarias y la normalidad de la urea plasmática a pesar de que el filtrado glomerular esté disminuido, además de la facilidad para presentar hiponatremia e hiperpotasemia (AU)


Asunto(s)
Adulto , Anciano , Femenino , Masculino , Anciano , Humanos , Túbulos Renales/fisiología , Pruebas de Función Renal/métodos , Sodio/orina , Urea/orina , Potasio/orina , Eritropoyetina/sangre , Valores de Referencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA